Harpoon Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Harpoon Therapeutics' es Julie Eastland , nombrado en Nov 2021, tiene una permanencia de 2.33 años. compensación anual total es $1.16M, compuesta por 48.7% salario y 51.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.016% de las acciones de la empresa, por valor de $80.60K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 5.5 años, respectivamente.
Información clave
Julie Eastland
Chief Executive Officer (CEO)
US$1.2m
Compensación total
| Porcentaje del salario del CEO | 48.7% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 1.4yrs |
| Promedio de permanencia en la Junta Directiva | 5.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$1m | US$565k | -US$68m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$75m |
| Dec 31 2021 | US$2m | US$84k | -US$117m |
Compensación vs. Mercado: La compensación total de Julie($USD1.16M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Julie ha sido consistente con los resultados de la empresa en el último año.
CEO
Julie Eastland (59 yo)
2.3yrs
Permanencia
US$1,160,774
Compensación
Ms. Julie M. Eastland, M.B.A. served as Chief Operating Officer and Chief Financial Officer at Recode Therapeutics, Inc. since October 2020 until November 2021. She serves as the President and Chief Execut...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.3yrs | US$1.16m | 0.016% $ 80.6k | |
| Chief Medical Officer | 1.4yrs | US$668.96k | 0% $ 0 | |
| Interim Chief Financial Officer | no data | sin datos | sin datos | |
| Senior Vice President of Product Development | 1.3yrs | sin datos | sin datos | |
| Chief Legal Officer | less than a year | sin datos | sin datos | |
| Chief People Officer | 1.7yrs | sin datos | sin datos | |
| Senior Vice President of Translational Medicine | 1.7yrs | sin datos | sin datos | |
| Senior Vice President of Business Development | less than a year | sin datos | sin datos |
1.4yrs
Permanencia media
56.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HARP no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.4yrs | US$1.16m | 0.016% $ 80.6k | |
| Independent Director | 6.8yrs | US$59.56k | 0.036% $ 179.5k | |
| Independent Director | 4yrs | US$58.56k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$37.76k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.5yrs | US$58.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman of the Board | 5.6yrs | US$109.62k | 0.083% $ 406.5k | |
| Independent Director | 4yrs | US$62.06k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$59.56k | 0.036% $ 179.5k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
5.5yrs
Permanencia media
58.5yo
Promedio de edad
Junta con experiencia: La junta directiva de HARP se considera experimentada (5.5 años de antigüedad promedio).